Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity (NCE) that has been shown in preclinical models to prevent demyelination, which is a hallmark of MS and other neurogenerative diseases and is characterized by damage to the myelin sheath surrounding nerve fibers.
'We are pleased to announce that we have signed this agreement with a leading CDMO to develop and manufacture an oral formulation of Lucid-MS. This marks an important step in the clinical development of Lucid-MS as we prepare the Investigational New Drug (IND) application with the FDA and prepare for our upcoming Phase 2 trial of Lucid-21-302 in MS,' said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains certain 'forward-looking statements' within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as 'plan,' 'continue,' 'expect,' 'project,' 'intend,' 'believe,' 'anticipate,' 'estimate,' 'may,' 'will,' 'potential,' 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements include the Company's belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStop's stock price. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStop stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@quantumbiopharma.comTelephone: (833) 571-1811
Investor Relations Investor Relations: IR@QuantumBioPharma.comGeneral Inquiries: info@QuantumBioPharma.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche
The United States Personalized Medicine Market is projected to soar to US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, experiencing a CAGR of 6.82% from 2025 to 2033. Key growth drivers include advances in next-generation sequencing, rising demand for customized treatments, and government policy support. The integration of technologies like AI and machine learning is enhancing precision in diagnostics and treatment, revolutionizing personalized healthcare. Market challenges include high development costs and limited clinical standardization. Major players such as Abbott Laboratories and Illumina, Inc., are at the forefront of this transformative sector. U.S. Personalized Medicine Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Personalized Medicine Market - Genomic Trends & Forecast 2025-2033" report has been added to States Personalized Medicine Market is expected to reach US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, with a CAGR of 6.82% from 2025 to 2033 Advances in next-generation sequencing, rising patient demand for customized treatments, the prevalence of chronic diseases, encouraging government policies, and rising investments in biotechnology and digital health technologies are some of the major factors propelling the US personalized medicine market. Innovations in digital health, biotechnology, and genomics are propelling the revolutionary expansion of the customized medicine sector in the United States. The goal of personalized medicine is to adjust medical care to each patient's unique traits, such as their environment, lifestyle, and genetic composition. With this strategy, healthcare is moving away from the conventional "one-size-fits-all" paradigm and toward more accurate, predictive, and preventative treatment. Healthcare providers and pharmaceutical firms are investing more in research and development to provide treatments with better efficacy and fewer side effects as a result of the increased emphasis on customized incorporation of advanced technologies like artificial intelligence, machine learning, and next-generation sequencing into clinical and research settings is a major factor driving this industry. Clinicians can use these technologies to find biomarkers, genetic mutations, and other molecular signs that help with diagnostic and treatment choices. The capacity to match patients with tailored therapies is also being improved by the growing availability of companion diagnostics, especially in intricate domains like neurology and cancer. Because of this, customized medicine is changing clinical procedures, encouraging early intervention, and facilitating better illness management in a variety of therapeutic domains. The industry is also being driven ahead by government assistance, changing regulations, and cooperation between the public and private sectors. The infrastructure required for the widespread adoption of customized healthcare is being built in part by initiatives to gather and analyze a variety of patient data. Additionally, healthcare practitioners are being prompted to embrace more patient-centric methods due to rising patient awareness and desire for customized treatment alternatives. The United States is now positioned as a worldwide leader in customized medicine, and these advancements are fostering an atmosphere that is conducive to innovation. Cost, data privacy, and accessibility issues still exist as the sector develops, but sustained cooperation and advancements in technology could help to overcome these obstacles and spur further Factors Driving the United States Personalized Medicine Market Growth Advancements in Genomic and Molecular TechnologiesAdvances in molecular diagnostics, bioinformatics, and genome sequencing are greatly speeding up the use of customized medicine in the United States. These technologies make it possible to identify biomarkers and genetic variants that aid in customizing treatment regimens for each patient. Patient genomes may now be analyzed more quickly and affordably thanks to next-generation sequencing and other high-throughput technologies. This reduces trial-and-error in therapy selection, which improves treatment results in addition to improving diagnostic accuracy. These technologies are being incorporated into standard clinical practice as they become more affordable and available, especially in areas like pharmacogenomics, uncommon illnesses, and cancer. This technical advancement is still a significant driver of market expansion for biopharmaceutical businesses, hospitals, and research Demand for Targeted TherapiesMore and more patients and medical professionals are looking for treatments that are tailored to each patient's unique health profile, especially for chronic or complicated illnesses like diabetes, autoimmune diseases, and cancer. A move toward more accurate, focused therapy has resulted from the unintended side effects and variable results of traditional treatments. In order to improve efficacy and safety, personalized medicine uses genetic and molecular data to anticipate a patient's response to certain therapies. Pharmaceutical firms are investing more in biologics and companion diagnostics as a result of the desire for customized treatment, which is also having an impact on drug development pipelines. The need for customized medicine is rising in all healthcare settings as more people become aware of the advantages of tailored Regulatory and Policy EnvironmentThe United States' regulatory environment has shifted in favor of customized medicine, fostering innovation and expediting the approval of focused treatments. Frameworks and criteria for assessing companion diagnostics and precision medicines have been created by organizations like the U.S. Food and Drug Administration (FDA). A solid basis for market expansion has been established by initiatives including national genome projects, public-private collaborations, and federal support for precision medicine research. The goal of these initiatives is to hasten the shift from conventional to individualized care models. Furthermore, the financial feasibility of customized medicine solutions is being further enhanced by continuous improvements in healthcare payment systems that are gradually opening up individualized therapies to a wider in the United States Personalized Medicine Market High Costs of Development and TreatmentCosts associated with personalized medicine are high, especially when it comes to research, genetic testing, and medication development. A substantial investment in clinical trials, genetic research, and regulatory approval procedures is necessary to develop customized treatments. Furthermore, many patients cannot afford the exorbitant cost of many customized treatments, particularly those involving biologics or cell and gene therapies. Additionally, the expense of sophisticated sequencing technology and companion diagnostics may prevent widespread usage in routine clinical settings. Both individuals and healthcare providers have financial difficulties as a result of these high costs, which frequently lead to inadequate insurance coverage. The high cost of customized medicine continues to be a significant obstacle to its wider adoption throughout the American healthcare system until more scalable and reasonably priced models are Standardization and Integration in Clinical PracticePersonalized medicine has not yet been completely incorporated into standard clinical care, despite its potential. The lack of uniformity in the interpretation and use of genomic data is a significant obstacle. Complex genetic information can be difficult for healthcare professionals to comprehend and use, especially in basic care settings. Furthermore, a large number of electronic health records (EHRs) lack the necessary tools for effectively managing or integrating genetic data. The lack of qualified experts, such as precision medicine specialists and genetic counselors, is another issue impeding broad adoption. The actual implementation of customized medicine in healthcare facilities is still uneven in the absence of uniform procedures, training, and smooth technology integration. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Abbott Laboratories GE Healthcare, Inc. Aadi Bioscience, Inc. Illumina, Inc. QIAGEN Eli Lilly and Company Takeda Pharmaceutical Company Ltd AbbVie Inc. F. Hoffmann-La Roche Ltd. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $169.56 Billion Forecasted Market Value (USD) by 2033 $307.04 Billion Compound Annual Growth Rate 6.8% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. United States Personalized Medicine Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product6.2 By Application6.3 By End Users7. Product7.1 Personalized Medicine Therapeutics7.2 Personalized Medicine Diagnostics7.3 Personalized Medical Care7.4 Personalized Nutrition and Wellness8. Application8.1 Oncology8.2 Infectious disease8.3 Neurology or Psychiatry8.4 Cardiovascular8.5 Others9. End Users9.1 Hospitals9.2 Diagnostic Centers9.3 Research & Academic Institutes9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Personalized Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, affecting over 3.4 million Americans, and advancements in drug development. Key players like Eisai, UCB, and Lundbeck emphasize second and third-generation AEDs offering improved safety and efficacy. Despite challenges like high treatment costs and regulatory hurdles, the market benefits from supportive FDA policies. Segmentation includes first, second, and third-generation drugs across various seizures and distribution channels. U.S. Epilepsy Drugs Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2025-2033" report has been added to States Epilepsy Drugs Market is expected to reach US$ 3.45 billion by 2033 from US$ 2.36 billion in 2024, with a CAGR of 4.31% from 2025 to 2033 In order to satisfy shifting customer needs, firms are being prompted by this transition to innovate and diversify their product lines. All things considered, the market for French-flavored milk is expected to grow further due to innovation, custom, and customer preferences. The market for epilepsy medications in the United States is a vibrant area of the larger neurology therapeutics business, with a wide range of antiepileptic medications (AEDs) that target different kinds of seizures. North America accounted for the greatest portion of the worldwide market for epilepsy medications in 2024, with the United States leading the way in terms of market size and revenue production. Due to their enhanced safety profiles and effectiveness, second-generation AEDs are growing at the quickest rate in the market, which is divided into first, second, and third-generation AEDs. The high demand for efficient treatment solutions is shown by the estimated 1.2% prevalence of epilepsy in the United prevalence of epilepsy has increased in the U.S. population. The seizures Foundation estimates that more than 3.4 million Americans suffer from seizures. Furthermore, 1 in 26 Americans are predicted to receive a diagnosis of epilepsy at some point in their lives, with over 150,000 receiving a diagnosis each year. New developments in medication development have accelerated the market's growth even further. The FDA's 2022 approval of ganaxolone (Ztalmy) for the treatment of seizures linked to CDKL5 deficient condition was a noteworthy milestone that provided a new therapeutic option for a patient population that had previously been underserved. Furthermore, the growing investment in specialist epilepsy medicines is demonstrated by Lundbeck's $2.6 billion acquisition of Longboard Pharmaceuticals in 2024, which was intended to develop bexicaserin for the treatment of developmental and epileptic encephalopathies. These advancements are in line with the demand for treatments that target complicated and uncommon epilepsy disorders as well as the increased emphasis on customized Factors Driving the United States Epilepsy Drugs Market Growth Increasing Prevalence of EpilepsyOne of the main factors propelling market growth is the increasing prevalence of epilepsy in the United States. It affects around 2.9 million individuals who are 18 years of age or older, with a significant incidence in youngsters. The need for efficient anti-epileptic medications (AEDs) is increased by this expanding patient base. Certain demographics, such as those from minority racial and ethnic groups and those with lower educational attainment, are more likely to have the syndrome. As more people look for medical intervention and treatment alternatives, the market is growing as a result of growing awareness and diagnosis of epilepsy. In order to satisfy the needs of a varied patient population, this trend emphasizes the necessity of ongoing innovation and accessibility in the creation and distribution of in Drug DevelopmentSecond and third-generation anti-epileptic medications (AEDs), which have better effectiveness and safety profiles, have been introduced as a result of ongoing research and development efforts. These more recent drugs aim to overcome the drawbacks of previous therapies by improving seizure control while reducing adverse effects. These developments not only improve patient outcomes but also provide medical professionals more treatment alternatives. The dedication to meeting the unmet requirements of the epilepsy community is seen in the ongoing pipeline of new AEDs, which propels market Regulatory EnvironmentFaster access to new medicines is made possible by the U.S. Food and Drug Administration's (FDA) accelerated approval of innovative anti-epileptic medications (AEDs). Pharmaceutical firms are encouraged to invest in the discovery of novel medicines by this regulatory assistance. Furthermore, programs like the Epilepsy Foundation's #RemoveTheFilter and National Epilepsy Awareness Month have raised public awareness and decreased stigma, which has encouraged more people to seek treatment. Because of these initiatives, the patient population is more informed, which increases the likelihood of diagnoses and treatment compliance. The market for epilepsy medications is expected to develop in a favorable environment because to a mix of supportive regulatory frameworks and increased public in the United States Epilepsy Drugs Market High Treatment Costs and Affordability IssuesAccess to therapy is severely hampered by the rising costs of antiepileptic medications (AEDs) in the US. For example, generic drugs are frequently less expensive than name-brand ones, such as Fycompa and Aptiom, which may cost thousands of dollars a month. Generics are not always readily available, and some more recent AEDs do not have generic counterparts, which keeps their prices high. Furthermore, insurance coverage might vary; Medicare seniors are frequently not eligible for co-pay assistance programs, and other plans have hefty deductibles or co-pays. These monetary difficulties may cause patients to stop taking their medications, which raises the risk of seizures and related problems. In order to provide fair access to efficient epilepsy therapies, it is imperative that these economic concerns be Hurdles and Market Entry DelaysNew antiepileptic medications (AEDs) must pass rigorous regulatory criteria enforced by the U.S. Food and Drug Administration (FDA), which include thorough documentation and lengthy clinical studies. For pharmaceutical firms, this stringent procedure may raise development costs and postpone the release of new medications. Furthermore, generic versions of important AEDs are introduced when their patents expire; although they are less expensive, they might not always satisfy the unique demands of every patient. People who need specialized care may have fewer alternatives due to these market factors. Additionally, market access and the profitability of AED development initiatives may be hampered by the drawn-out and expensive approval procedures linked to regulatory obstacles. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Eisai Co., Ltd. UCB Inc. H. Lundbeck A/S GW Pharmaceuticals Plc. Abbott Laboratories Alkem Laboratories Limited Bausch Health Companies Inc. GSK plc Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $2.36 Billion Forecasted Market Value (USD) by 2033 $3.45 Billion Compound Annual Growth Rate 4.3% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Exploring the Disease - Background and Key Insights5.1 Introduction5.2 Causes5.3 Classification of Epilepsies5.3.1 West Syndrome5.3.2 Dravet syndrome5.3.3 Lennox-Gastaut syndrome5.3.4 Landau-Kleffner syndrome5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)5.3.6 CDKL5 deficiency disorder (CDD)5.4 Risk Factors5.5 Pathophysiology5.6 Diagnosis5.6.1 Diagnostic Guidelines5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)5.6.1.3 The French National Authority for Health (HAS): 20205.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)5.7 Treatment5.7.1 Antiepileptic Medications (AEDs)5.7.2 Receptor Blockers5.7.3 Others5.7.4 Diet Therapy5.7.5 Surgery5.7.5.1 Phase I Evaluation (Noninvasive Tests)5.7.5.2 Phase II Evaluation (Invasive Mon)5.7.6 Treatment Algorithm for Medical Condition5.7.7 Treatment Guidelines5.7.7.1 American Epilepsy Society5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines5.7.7.4 NICE Guidelines: (2022)5.7.8 Living and Coping with Epilepsy6. United States Epilepsy Drugs Market6.1 Historical Market Trends6.2 Market Forecast7. Market Share Analysis7.1 By Drugs Category7.2 By Seizure types7.3 By Distribution Channels8. Drugs Category8.1 First Generation Drugs8.2 Second Generation Drugs8.3 Third Generation Drugs9. Seizure Types9.1 Focal Seizures9.2 Generalized Seizures9.3 Non-Epileptic Seizures10. Distribution Channels10.1 Hospital Pharmacies10.2 Drug Stores and Retail Pharmacies10.3 Online Providers11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Analysis of Marketed Medications/Drugs13.1 Key Players13.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals13.2.1 Description of Drugs13.2.2 Regulatory Milestones13.2.3 Clinical Development Process13.2.4 Safety and Efficacy13.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical13.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku13.5 NAYZILAM (midazolam) nasal spray - UCB Pharma13.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma13.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion13.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma13.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical13.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals13.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo14. Analysis of Emerging Drugs14.1 Key Cross Competition14.2 XEN1101 - Xenon Pharmaceuticals14.2.1 Description of Drug14.2.2 Clinical Research & Development14.2.3 Safety and efficacy14.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)14.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics14.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)14.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences14.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals14.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals14.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals15. Regulations and Reimbursement Policies16. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Epilepsy Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Is Occidental Petroleum a Buy on the Dip?
Key Points Occidental Petroleum made a huge splash when it outbid Chevron to buy Anadarko Petroleum. Oxy's business hit a rough patch shortly after the Anadarko deal, but it has a more clear direction now. The energy company isn't as big as some of its peers, but it is working hard to bulk up. 10 stocks we like better than Occidental Petroleum › The name Occidental Petroleum (NYSE: OXY) gets more attention than it used to, thanks to the involvement of Warren Buffett and Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), the company Buffett runs. Given the Oracle of Omaha's fame as an investor, some might buy Occidental Petroleum for this fact alone. But you'll probably want to get a bit more of an understanding here, because Buffett also owns Chevron (NYSE: CVX), a far larger energy company. There's a lot to unpack. Why did Buffett get involved in Occidental Petroleum? Occidental Petroleum has a market cap of around $40 billion, which makes it a large company but a relatively small energy business. To put some perspective on that, ExxonMobil is an industry giant and has a market cap of roughly $450 billion. Chevron, for reference, has a market cap of around $300 billion. Why does size matter here? Because all three energy companies use the same basic business model. They are what are known as integrated energy companies, with operations that span from the upstream (energy production), through the midstream (pipelines), and all the way to the downstream (chemicals and refining). They are, therefore, competitors, with Oxy, as it is more commonly known, the small fry. But Oxy managed to punch above its weight in 2019 when it bought Anadarko out from under Chevron. That's when Buffett and Berkshire Hathaway got involved, helping to finance Oxy's winning bid for Anadarko. It was a huge sign that Oxy isn't happy living in the shadows -- it wants to grow so it can better compete with the energy sector's largest players. The growth opportunity here is why you buy Oxy. The problem with Occidental Petroleum There are some important nuances here, though. For example, the purchase of Anadarko left Oxy's balance sheet in a weakened state. When oil prices crashed during the coronavirus pandemic in 2020, the company was forced to cut its dividend. However, Oxy has worked hard to strengthen its financial position. And it has already gotten back on the growth via acquisition track. That said, this growth-oriented energy company has a somewhat modest dividend yield of 2.2%. Exxon's yield is 3.7%, while Chevron's yield is 4.4%. Clearly, if you are buying Oxy, you are buying for the growth, not the income. Which brings up an interesting twist: Buffett owns Oxy, but he also owns Chevron. So if you want to invest like Buffett, you could literally buy either one. Compared to Oxy, Chevron is a slow and steady tortoise, noting that the company has increased its dividend annually for 38 consecutive years. While Chevron offers income, size, and stability, it doesn't offer the same growth prospects. Sure, Chevron will buy other companies, noting it recently acquired Hess. But the vast scale of its operations means such deals won't likely have the same growth impact on its business as will Oxy's acquisitions. Right now, geopolitical events have left energy prices in a state of flux. Over the past year, Chevron's stock has fallen around 5%. Oxy's shares are down over 20%! Given the difference in the sizes of these two integrated energy businesses and Oxy's focus on growth, this disparate performance isn't really shocking. Oxy is a riskier energy stock, and Wall Street is treating the shares appropriately in an uncertain period for energy prices. Oxy could be a buy, for the right investor Buffett, however, hasn't given up on Oxy. That is a huge vote of support, noting that the Oracle of Omaha likes to hold companies for the long term so he can benefit from the growth of a business over time. Oxy probably won't appeal to conservative investors or those with an income focus (Chevron would be the better choice). However, if you lean into growth, this dip could be an interesting opportunity to invest alongside Warren Buffett and Berkshire Hathaway while Oxy's stock is trading hands more cheaply. Should you buy stock in Occidental Petroleum right now? Before you buy stock in Occidental Petroleum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Occidental Petroleum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway and Chevron. The Motley Fool recommends Occidental Petroleum. The Motley Fool has a disclosure policy. Is Occidental Petroleum a Buy on the Dip? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
